Company intelligence / Profile preview

Shandong Chuangxin Pharmaceutical

Jinan, Shandong, China

Ownership: Private
Development stage: Other

Overview

Shandong Chuangxin Pharmaceutical Research and Development Co., Ltd. is a Chinese pharmaceutical company engaged in the development and evaluation of generic drugs. The company has been involved in clinical trials to assess the bioequivalence of its generic formulation of ezetimibe + atorvastatin calcium compared to the branded product (Atozet) in healthy Chinese adults, aiming to demonstrate equivalent pharmacokinetics and safety[3].

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Jiangxi Shimei Pharmaceutical Co., Ltd.

Beyond the preview

Go deeper on Shandong Chuangxin Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shandong Chuangxin Pharmaceutical.

Explore the full profile